

Vessl therapeutics advanced cell therapy
Moshe Flugelman, MD, Vessl therapeutics

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
We are using cell- and gene-based proprietary technologies along with the body's own healing mechanisms to develop solutions for vascular-related conditions that are effective and faster to recover from. Our breakthrough solutions are aimed for people suffering from advanced peripheral arterial disease, problems with their dialysis access sites and many other conditions.

- **Business Strategy**
Our products address hundreds of thousands of patients globally. Manufacturing of our cell-based products will take place in several manufacturing facilities, each located in regions serving 100,000 patients that are candidates for our therapies. Market size globally for our leading arteriogenesis therapy is estimated to be \$30b.

- **Core Technology**
Product Profile/Pipeline
Our therapies are derived from the patient's own cells isolated from a short vein segment taken from their arm under local anesthesia. These cells are activated by the insertion of specific genes and are then re-introduced to the patient. Our pioneering approach enables the secretion of multiple factors by the activated autologous cells, closely mimicking the natural process of blood vessel formation and growth.

- **What's Next?**
Vessl therapeutics completed two phase 1 studies in the US and Israel and is seeking financial resources to initiate its placebo controlled study of MGA in patients with critical limb ischemia.